Company news

Shield Therapeutics PLC news in 2025

Shield Therapeutics PLC's news releases, calls and decks from 2025, newest first.

View company

FDA approves extension for ACCRUFeR®

December 22, 2025

Block Listing Application

December 18, 2025

Shield Wins Gold at Titan Branding Awards

December 11, 2025

Amends Senior Secured Debt Financing

December 3, 2025

Initiation of a Phase II Clinical Trial in Japan

November 14, 2025

ACCRUFeR Pediatric PK Results to be Presented

November 11, 2025

ACCRUFeR receives Authorisation by Korean Ministry

November 7, 2025

Q3 2025 Trading Update

October 24, 2025

Q3 2025 Trading Update

October 23, 2025

Grant of Share Options to Chief Executive Officer

October 14, 2025

Positive efficacy and tolerance in pediatric trial

October 1, 2025

£1.5 million placing supporting growth of ACCRUFeR

September 15, 2025

ACCRUFeR® assigned Priority Review in US by FDA

September 4, 2025

Interim results for the six months ended 30 Jun 25

September 3, 2025

Data published -European Journal of Heart Failure

August 27, 2025

Shield Therapeutics: Interim results for the six months ended 30 June 2025

August 21, 2025

Q2 2025 Trading Update

July 23, 2025

Result of AGM

May 22, 2025

Annual Report and Accounts for the year ended 2024

April 25, 2025

Audited results for the year ended 31 Dec 2024

April 24, 2025

Licence Agreement in Japan for ACCRUFeR®

April 22, 2025

Q1 2025 Trading Update

April 17, 2025

ACCRUFeR® launched in Canada

March 11, 2025

PDMR Transaction Notification

February 13, 2025

Unaudited full year trading update

February 5, 2025

Anders Lundstrom appointed CEO

January 27, 2025

Calls in 2025

Decks in 2025